2022
Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out.
Punekar S, Weber J. Intratumoral Therapy to Make a "Cold" Tumor "Hot": The Jury Is Still Out. Clinical Cancer Research 2022, 28: 5007-5009. PMID: 36161479, DOI: 10.1158/1078-0432.ccr-22-2427.Peer-Reviewed Original ResearchThe current state of the art and future trends in RAS-targeted cancer therapies
Punekar S, Velcheti V, Neel B, Wong K. The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology 2022, 19: 637-655. PMID: 36028717, PMCID: PMC9412785, DOI: 10.1038/s41571-022-00671-9.Peer-Reviewed Original ResearchConceptsDuration of responseNovel combination therapiesCombination therapyClinical trialsTherapeutic strategiesSolid tumorsMutant KRASTumor microenvironmentDrug resistanceRAS pathwayCancer cellsDevelopment of inhibitorsCancer therapyOncogenic RASPatientsOncogenic proteinsTherapyKRASResistance mechanismsMutant isoformsInhibitorsRASMalignancyTumorsCancerPD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.
Shu F, Punekar S, Velcheti V, Sanmamed M, Wang J. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy. Clinical Cancer Research 2022, 28: 3182-3184. PMID: 35648093, DOI: 10.1158/1078-0432.ccr-22-0541.Peer-Reviewed Original Research
2019
Novel Therapeutics Affecting Metabolic Pathways
Punekar S, Cho D. Novel Therapeutics Affecting Metabolic Pathways. American Society Of Clinical Oncology Educational Book 2019, 39: e79-e87. PMID: 31099667, DOI: 10.1200/edbk_238499.Peer-Reviewed Original ResearchConceptsIntratumoral metabolic heterogeneityMetabolic heterogeneityImmune factorsNovel agentsTherapeutic strategiesTumor microenvironmentNovel therapeuticsDistinct metabolic characteristicsCancer cellsMetabolic characteristicsCombination strategiesNormal cellsCell growthSpecific metabolic processesCitric acid cycle